Eli Lilly and Company and ARMO BioSciences announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion,
ARMO BioSciences announced the appointment of Naiyer A. Rizvi, M.D. to its Board of Directors. Dr. Rizvi is the Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy in the Division of Hematology and Oncology at Columbia University Medical